Nobuyuki Yamamoto

机构：Kansai Medical University, Wakayama Medical University, Indiana University Bloomington, Hokuto Hospital, Kobe University · ORCID：0000-0002-7342-0853

发表论文 1049 篇 · 总被引 29850 次 · h-index 76

代表论文

• Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study (2025 · The Lancet Oncology · 被引 5)
• Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations (2025 · Lung Cancer · 被引 3)
• Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L (2025 · Clinical Lung Cancer · 被引 2)
• Real-world adherence to antiemetic guidelines in Japanese patients receiving high or carboplatin-based moderate emetic risk chemotherapy (2025 · International Journal of Clinical Oncology · 被引 2)
• Directed Amination as a Strategy for C–N Bond Formation by Iron Imido Complexes (2026 · Inorganic Chemistry)
• Supplementary Figure 4 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC (2026)